Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT5P-FT2P phage cocktail
- Development stage
- Preclinical
- Lead developer
- CIBERINFEC
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
The FT5P-FT2P phage cocktail is a dual-phage therapeutic candidate consisting of a 1:1 mixture of the bacteriophages FT5P and FT2P. It is being developed for the treatment of infections caused by vancomycin-resistant *Enterococcus faecium* (VREfm) and *Enterococcus faecalis*. The cocktail is designed to expand the therapeutic host range and enhance anti-biofilm efficacy compared to single-phage monotherapies, showing stable coexistence of both phages without competitive inhibition. Preclinical studies conducted by researchers at the IIS-Hospital Universitario Fundación Jiménez Díaz and CIBERINFEC in Spain demonstrate that the cocktail can successfully eradicate susceptible planktonic bacterial strains and significantly disrupt established biofilms.
- Other names
- FT5P-FT2P cocktailFT-5P-FT2P cocktailFT 5P-FT2P cocktailFT5P-FT2P dual-phage cocktailFT-5P-FT2P dual-phage cocktailFT 5P-FT2P dual-phage cocktail
Beyond the preview
Go deeper on FT5P-FT2P phage cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT5P-FT2P phage cocktail.